Anti-CD19-CAR T cells (Beijing Doing Biomedical)

N/A

Report date: 2022/11/02 16:12:50

Base Information

Drug NameAnti-CD19-CAR T cells (Beijing Doing Biomedical)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Doing Biomedical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Doing Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A